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This st�dy describes a 32 f�ll factorial experimental design to optimize the form�lation of dithranol 
(DTH) loaded solid lipid nanoparticles (SLN) by the pre�em�lsion �ltrasonication method. The variables 
dr�g� lipid ratio and sonication time were st�died at three levels and arranged in a 32 factorial design to 
st�dy the infl�ence on the response variables particle size and % entrapment efficiency (%��). From 
the statistical analysis of data polynomial eq�ations were generated. The particle size and %�� for the 9 
batches (R1 to R9) showed a wide variation of 219�348 nm and 51.33� 71.8� %, respectively. The physical 
characteristics of DTH�loaded SLN were eval�ated �sing a particle size analyzer, differential scanning 
calorimetry and X�ray diffraction. The res�lts of the optimized form�lation showed an average particle 
size of 219 nm and entrapment efficiency of 69.88 %. Ex-vivo dr�g penetration �sing rat skin showed 
abo�t a 2�fold increase in localization of DTH in skin as compared to the marketed preparation of DTH.
Uniterms: Solid lipid nanoparticles. Homogenization. Ultrasonication. 32 factorial design. Dithranol.
�ste est�do descreve o planejamento factorial 32 para otimizar a form�lação de nanopartíc�las lipídicas 
sólidas (SLN) carregadas com ditranol (DTH) pelo método da �ltrassonificação pré�em�lsão. As 
variáveis como proporção de fármaco�lipídio e o tempo de sonicação foram est�dados em três níveis 
e arranjados em planejamento fatorial 32  para est�dar a infl�ência nas variáveis de resposta tamanho 
de partíc�la e eficiência percent�al de retenção do fármaco (%��). Pela análise estatística, geraram�se 
eq�ações polinomiais. O tamanho da partíc�la e a %�� para os 9 lotes (R1 a R9) mostraram ampla 
variação, respectivamente, 219�348 nm e 51,33�71,8�%. As características físicas das SLN carregadas 
com DTN foram avaliadas �tilizando�se analisador de tamanho de partíc�la, calorimetria de varred�ra 
diferencial e difração de raios X. Os res�ltados da form�lação otimizada mostraram tamanho médio de 
partíc�la de 219 nm e eficiência de retenção do fármaco de 69,88%. A penetração ex vivo do fármaco 
�tilizando pele de rato mostro� a�mento de, aproximadamente, d�as vezes na localização de DTH na 
pele, comparativamente à preparação de DTH comercializada. 
Unitermos: Nanopartíc�las lipídicas sólidas. Homogeneização. Ultrasonicação.   Planejamento fatorial. 
Ditranol. 
INTRODUCTION
Solid lipid nanoparticles (SLN) were developed at 
the beginning of the 199�s as an alternative carrier system 
to the existing traditional carriers, s�ch as em�lsions, lipo�
somes and polymeric nanoparticles (Müller et al., 1995). 
Solid lipid nanoparticles (SLN) are the new generation of 
nanopartic�late active s�bstance vehicles and are attracting 
major attention as novel colloidal dr�g carriers for topical 
�se. Small lipid vesicles in the range of nanometers have 
advantages, b�t avoid the disadvantages, of other colloidal 
carriers (Utreja, Jain, 2��1). Compared with polymeric 
nanoparticles, SLN have lower toxicity beca�se of the 
absence of solvents in the prod�ction process and also rela�
tively low cost excipients. SLN offer combined advantages 
s�ch as controlled release, biodegradable, negligible skin 
irritation and protection of active compo�nds. (Müller, 
Mäder, Gohla, 2���; Sylvia, Müller, Wissing, 2��3). The 
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major advantage of SLN is the possibility of prod�ction 
on an ind�strial scale (Müller, Lippacher, Gohla, 2���). 
The lipids which are �sed in making these carriers have an 
approved stat�s, offer low systemic toxicity and also low 
cytotoxicity (Müller, et al., 1997). Moreover, the small 
particle size of SLN ens�re close contact with the strat�m 
corne�m (SC), th�s increasing penetration of encaps�lated 
active agent into the skin (Mei et al., 2��3). 
SLN have been reported to improve the photo 
stability and skin permeation of tretinoin (Shah, et al., 
2��7), provide a good skin targeting effect and constit�te 
a promising carrier for topical delivery of penciclovir (Lv, 
et al., 2��9) and podophyllotoxin (Chen, et al., 2��6), as 
well as red�ce skin irritation on topical application (Maia, 
et al., 2���; Sivaramakrishnan, et al., 2��4).
Psoriasis is one of the most common h�man skin 
diseases and is considered to have key genetic �nderpin�
nings. �t is characterized by excessive growth and aberrant 
differentiation of keratinocytes (Lowes, Bowcock, Kr�e�
ger, 2��7). Dithranol or Anthralin is a hydroxyanthrone, 
anthracene�derivative medicine applied to the skin of in�
divid�als with psoriasis, exhibiting both anti�proliferative 
and anti�inflammatory properties. Dithranol acc�m�lates 
in mitochondria, res�lting in a red�ction of adenosine 
triphosphatase (ATP) synthesis, which leads to inhibition 
of DNA replication and repair and hence slows the exces�
sive cell division that occ�rs in psoriatic plaq�es (Gerrit�
sen, 2��7). �n addition, modification of DNA bases and 
inhibition of vario�s enzymes have also been described. 
�pidermal calmod�lin has been reported to be elevated 
in psoriasis. Dithranol was demonstrated to be a potent 
competitive antagonist of calmod�lin. (T�cker et al., 
1986). SLN appears to be an interesting vehicle for topical 
administration of DTH (Carlotti et al., 2��9). SLN co�ld 
protect DTH from degradation ca�sed by UVA irradiation.
The objective of this st�dy was to develop a mathe�
matical model �sing 32 experimental design in order to 
ded�ce the adeq�ate conditions for preparation of DTH�
loaded SLN with desired characteristics able to improve 
the localization of DTH in skin. Ex-vivo penetration and 
localization of the optimized form�lations with maxim�m 
dr�g entrapment efficiency and minim�m particle size 
were also examined.
MATERIAL AND METHODS
Material
Compritol 888 ATO was obtained as a gift sample 
from Gattefosse (France). Tween 8�, Span 6�, glyceryl 
monostearate (GMS) and poloxamer 4�7 were provided by 
LOBA CH�M��, �ndia. Dithranol was donated by Glen�
mark, Washi, M�mbai (�ndia). All other chemicals were 
of reagent grade and �sed witho�t f�rther p�rification.
Preparation of SLN
SLN were prepared by pre�em�lsion followed by 
the �ltrasonication method (Fang, et. al., 2��8). Briefly, 
lipid phase consisted of dithranol, Compritol 888 ATO and 
Span 6� (3% w/v) maintained at 7� °C. An aq�eo�s phase 
was prepared by dissolving poloxamer 4�7 (3% w/v) in 
distilled water (s�fficient to prod�ce 5� ml of preparation) 
and heated to the same temperat�re as oil phase. Hot 
aq�eo�s phase was added to oil phase and homogenization 
was carried o�t at a temperat�re of 7�°C �sing an Omni 
TH homogenizer (Make Omni USA) at 46564.7 ×g for 3 
min. Coarse hot oil in water em�lsion th�s obtained was 
s�bjected to f�rther size red�ction �sing an �ltrasonicator 
(make Sonic VCX 75�, USA) for 1��3� min.
Experimental design and statistical analysis
Most form�lation st�dies involve variation of one 
factor at a time, keeping other factors constant. Factorial 
design enables all factors to be varied sim�ltaneo�sly, allo�
wing q�antification of the effects ca�sed by independent 
variables and interactions between them. �n this st�dy, a 32 
f�ll factorial experimental design was introd�ced to opti�
mize the form�lation of nanoparticles. �nitial st�dies were 
�ndertaken to decide on the excipients and their levels in 
the experimental design. 
The choice of lipid was made on the basis of sol��
bility and partitioning of dithranol in the lipid. Aq�eo�s 
phase s�rfactant and lipid phase s�rfactant were selected 
on the basis of stability of dispersion prepared by �sing 
different s�rfactants.
�n order to optimize the preparation of form�lations, 
the dr�g� lipid ratio (X1) and sonication time (X2) were 
chosen as independent variables. These two factors that 
might affect the nanoparticle form�lation and three levels 
of each factor were selected (Table �) and arranged accor�
ding to a 32 f�ll factorial experimental table (Table ��).
TABLE I - �ndependent variables and their selected levels for 
nanoparticles form�lation
Factor Coded level
�1 � +1
Dr�g� lipid ratio (X1) 1�3 1�5 1�7
Sonication time (X2) (min.) 1� 2� 3�
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Evaluation of solid lipid nanoparticles
Particle size analysis
The particle size analysis of the form�lations was 
performed �sing a Malvern Mastersizer 2��� MS device 
(Malvern �nstr�ments, Worcestershire, UK) and laser 
diffraction with a beam length of 2.4� mm, range lens of 
3�� RF mm, at 14.4% obsc�ration. The mean diameter of 
each batch is recorded in Table ���. 
Entrapment efficiency
For determination of entrapment in SLNs, the dr�g 
loaded lipid nanoparticles were separated from free dr�g 
by �ltra�centrif�gation (Beckmann �nstr�ments, �taly) at 
abo�t 158476.5 ×g. Free dr�g, determined spectrophoto�
metrically from the added dr�g, remained �nentrapped in 
s�pernatant liq�id which was obtained after �ltra�centri�
f�gation. The collected samples were added in chloroform 
and warmed to dissolve completely, and then extracted 
with dimethyl formamide (DMF) which dissolved only 
dithranol. The sol�tion was filtered, dil�ted with methanol 
and dithranol content determined spectrophotometrically.
�� was calc�lated according to the following eq�ation�
  Amo�nt of entrapped dr�g in SLN
 ��% =  ——————————————— × 1��
  Amo�nt of entrapped dr�g in SLN
  and free dr�g in dispersion
Differential Scanning Calorimetry (DSC) study
Differential Scanning Calorimetry (DSC) was per�
formed on a Mettler�Toledo DSC 821e (Col�mb�s, OH) 
instr�ment, and an empty standard al�min�m pan was �sed 
as reference. DSC scans were recorded at a heating rate of 
1� °C/min in a temperat�re range of 3��3�� °C. DSC mea�
s�rements were carried o�t on p�re compritol 888 ATO and 
dithranol as b�lk material and SLN loaded with dithranol.
X-ray diffraction
X�ray scattering meas�rements were carried o�t with 
a Philips PAN analytical expert PRO X�ray diffractometer 
178�. The samples were irradiated with mono�chromati�
zed C�Ka radiation and analyzed between 2�8� ºC 2Ø. The 
patterns were collected with voltage of 3�kV and c�rrent 
of 3� mA, respectively. The scanning rate (2Ø/min) was 
set at 1� ºC/min. 
Fourier Transmission Infrared Spectroscopy (FTIR) studies
A Jasco FT�R spectrophotometer (Jasco FT�R� 4�1, 
Japan) was �sed for infrared analysis of samples. Abo�t 
1�2 mg of sample was mixed with dry potassi�m bromide 
and the samples were examined at transmission mode over 
a wave n�mber range of 4��� to 4��cm�1. FT�R st�dies 
were carried o�t on p�re compritol 888 ATO and dithranol 
as b�lk material and SLN loaded with dithranol.
Ex-vivo skin penetration studies
Ointment containing DTH�loaded SLN was prepa�
red with white soft paraffin. Ointment containing plain 
DTH (marketed form�lation) was acq�ired from the ma�
rket. Ex-vivo skin penetration st�dies of DTH ointment 
were performed with rat skin (Li�, et al., 2��7; Shah, et al., 
2��7; Lv, et al., 2��9) �sing Franz diff�sion cell. Rat skin 
was taken from the abdominal region, after removing hair 
and s�bc�taneo�s fat tiss�e, by p�nching o�t a disc of ap�
proximately 2.5�cm2 in area. This slice was mo�nted on the 
Franz diff�sion cell. Phosphate b�ffer (pH 7.4) served as 
receptor fl�id. A small q�antity (�.1 g) of the ointment was 
applied to the skin s�rface. Serial sampling was performed 
at specified time intervals (1,2,3,4,5,6,7,8,9,1�,12 ho�rs) 
by removing the contents of the receptor compartment 
and replacing it with fresh medi�m. The samples were 
analyzed �sing UV�V�S spectrophotometer (Shimadz� UV 
18��) and mean c�m�lative amo�nt diff�sed Q (mg/cm2) 
at each sampling time point was calc�lated. At the end of 
12 ho�rs, the amo�nt of dr�g in the receptor compartment, 
the dr�g remaining on the skin, and the dr�g concentration 
in the skin was determined by extraction into a s�itable 
solvent followed by spectrophotometric analysis �sing an 
UV�V�S spectrophotometer.
RESULTS AND DISCUSSION
Experimental design and statistical analysis
The objective of this st�dy was to prepare solid li�
pid nanoparticles of dithranol by pre�em�lsion �ltrasoni�
cation method and to optimize the effects of form�lation 
variables on response parameters. Based on preliminary 
TABLE II - A 32 F�ll factorial experimental design layo�t
Form�lation Code Coded Factor Level
Factor 1 Factor 2
R1 �1 �1
R2 � �1
R3 1 �1
R4 �1 �
R5 � �
R6 1 �
R7 �1 1
R8 � 1
R9 1 1
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st�dies, compritol 888 ATO, Span 6� and Poloxamer 4�7 
were chosen as lipid, lipid phase s�rfactant and aq�eo�s 
phase s�rfactant respectively. Dr�g�lipid ratio and soni�
cation time were selected as variables and entrapment 
efficiency and particle size as response parameters. A 
32 f�ll factorial design was selected as it helps st�dy the 
effect on response parameters by changing both variables 
sim�ltaneo�sly with a minim�m n�mber of experimental 
r�ns.
The particle size and �� for the 9 batches (R1 to R9) 
showed a wide variation 219�348 nm and 51.33� 71.�8%, 
respectively (Table ���). The data clearly indicated strong 
dependence of response variables on the selected inde�
pendent variables.
�n order to q�antify the effect of form�lation varia�
bles on the response parameters, it was necessary to cons�
tr�ct a mathematical model which wo�ld help in predicting 
val�es of response parameters at any selected val�es of 
form�lation variables within the bo�ndaries of the design. 
�t may be the case that the levels of form�lation variables 
which are intermediate between the selected levels yield 
optim�m form�lation. Design �xpert 7.1 software was 
�sed to generate a mathematical model for each response 
parameter and the s�bseq�ent statistical analysis.
The coefficients of the polynomial eq�ations genera�
ted �sing MLRA (Design expert 7.1) for particle size and 
%�� of DTH�loaded SLN dispersion st�died are listed in 
(Table �V) along with the val�es of r2. Five coefficients (a 
to e) were calc�lated with k as the intercept. 
Y= k + aX1 + bX2+ cX1 X2 + dX1
2
 + eX2
2 (1)
The eq�ation was �sed to obtain estimates of the res�
ponses at vario�s factor combinations, where the optim�m 
combination was fo�nd to be similar to that corresponding 
to R7 and hence R7 was treated as the optimized batch.
For particle size response, the Model F�val�e of 
15.55 implies the model is significant.  There is only a 
2.35% chance that a “Model F�Val�e” this large co�ld 
occ�r d�e to noise. P val�e were fo�nd to be �.�235, 
with a val�e less than �.�5�� indicating model terms are 
significant.
The “Predicted R�Sq�ared” of �.6�33 is in rea�
sonable agreement with the “Adj�sted R�Sq�ared” of 
�.9��9.”Adeq Precision” meas�res the signal to noise ra�
tio.  A ratio greater than 4 is desirable.  The ratio of 11.2�7 
indicates an adeq�ate signal th�s the proposed model can 
be �sed to navigate the design space. 
For %�� response, the Model F�val�e of 26.66 
implies the model is significant.  There is only a 1.�9% 
chance that a “Model F�Val�e” this large co�ld occ�r d�e 
to noise. P val�e were fo�nd to be �.�1�9, with a val�e 
less than �.�5�� indicating model terms are significant.
The “Predicted R�Sq�ared” of �.7614 is in rea�
sonable agreement with the “Adj�sted R�Sq�ared” of 
�.9413.”Adeq Precision” meas�res the signal to noise ra�
tio.  A ratio greater than 4 is desirable.  The ratio of 12.862 
indicates an adeq�ate signal.  Th�s the proposed model can 
be �sed to navigate the design space.
Since the val�es of r2 are relatively high for both 
the responses, i.e., �.9629 for particle size and �.978� for 
%��, the polynomial eq�ations form an excellent fit to 
the experimental data and are highly statistically valid.
Three�dimensional response s�rface plots for each 
response parameter were constr�cted to st�dy the effects 
of both form�lation variables sim�ltaneo�sly along with 
the behavior of the system.
Fig�re 1 shows response s�rface plot for particle 
size. �t can be observed from the fig�re that dr�g� lipid 
ratio had a positive effect on particle size i.e. particle size 
TABLE III - Val�es of particle size and entrapment efficiency of 
DTH�loaded SLN (R1� R9) as per f�ll factorial design
Form�lation code Particle size (nm) % ��
R1 339 51.33
R2 348 54.8
R3 342 7�.3
R4 249 56.�5
R5 263 57.5
R6 319 69.5
R7 219 69.88
R8 247 6�.98
R9 285 71.8�
TABLE IV - Val�es of coefficients for polynomial eq�ations and 
r2 for vario�s response variables of DTH�loaded SLN
Coefficient 
code
Polynomial coefficient val�es for 
response variables
Particle size �ntrapment efficiency
k +272.89 +56.32
a +23.17 +5.72
b �46.33 +4.37
c +15.75 �4.26
d +6.17 +7.�5
e +19.67 +2.16
r2 �.9629 �.978�
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increased with increase in dr�g� lipid ratio. Least particle 
size was observed at the lowest level of dr�g�lipid ratio. 
A greater amo�nt of lipid may have res�lted in increasing 
the size of SLN.
Sonication time had the opposite effect on particle 
size. �t can be observed from Fig�re 1 that particle size de�
creased with increased sonication time. Fig�re 1 indicates 
that the sonication time had a greater impact on particle 
size compared to lipid content, moreover the effect of lipid 
content was more prono�nced at a high level of sonication 
which might be d�e to less effort req�ired to disperse the 
small lipid agglomerates. At low sonication time, lipid 
concentration had little infl�ence.
Fig�re 2 shows sim�ltaneo�s effect of sonication 
time and dr�g� lipid ratio on entrapment efficiency. �t can 
be observed that �� increased with increased sonication 
time. �ncreased sonication time res�lted in decreased 
particle size thereby increasing the total s�rface area and 
favoring entrapment. Dr�g� lipid ratio also had a similar 
effect. The val�e of �� was maximal when both form�la�
tion variables were employed at their highest levels. The 
reasons can be attrib�ted to the maxim�m amo�nt of lipid 
present for entrapment of the dr�g. The effect of sonication 
on entrapment was not evident at high lipid levels. At low 
lipid levels however, the decrease in sonication red�ced 
entrapment which may be acco�nted for by less availabi�
lity of lipid and decrease in lipid phase sol�bility of dr�g 
d�e to red�ced sonication.
Evaluation of solid lipid nanoparticles
Particle size analysis
The d (9�) for nanopartic�late dispersions showed 
a size ranging from 219 – 348 nm (Table ���). The effect 
of lipid concentration on the particle size is evident from 
the particle size of samples R3, R6 and R9 (342 nm, 319 nm 
and 285 nm, respectively) where it is at high level and so�
nication time is at low, middle and low levels. Samples R4 
FIGURE 1 - Three�dimensional response s�rface plots for particle size.
FIGURE 2 - Three�dimensional response s�rface plots for entrapment efficiency.
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and R7 with low lipid concentration (1�3) had the smallest 
particle size of between 2�� � 3�� nm. The sonication time 
shows a negative infl�ence on particle size. Particle size 
distrib�tion of the optimized batch is shown in Fig�re 3.
The second pop�lation of particles, as shown in the 
above fig�re, may be d�e to inadeq�ate sonic energy at the 
periphery of the dispersion or to particle growth d�ring the 
time period between sonication and size analysis.
Entrapment efficiency
A high amo�nt of dr�g was incorporated in nano�
particle dispersion. The %�� of different form�lations 
prepared (Table ���) indicates the positive infl�ence of 
lipid content on dr�g entrapment. The form�lations R3, 
R6 and R9 which have lipids at high level b�t s�rfactant 
at low middle and high levels, respectively showed % 
entrapment of 7�.3, 69.5 and 71.8�, respectively. This 
indicates overwhelming infl�ence of lipid on entrapment, 
irrespective of s�rfactant content. Form�lations R1, R4, 
which had lipid content at low level and s�rfactant at low 
and medi�m level, respectively show less % �� (< 6�%). 
For form�lation R7, the effect of high s�rfactant level 
was evident in the form of higher entrapment (69.88%). 
The partitioning of dr�g between lipid and water phases 
d�ring pre�em�lsion formation affects dr�g entrapment 
in nanoparticles. This in t�rn depends on the amo�nt of 
lipid, sol�bility of dr�g in lipid, process temperat�re and 
s�rfactant concentration. Therefore, the positive infl�en�
ce of lipid content on entrapment is explained.
Differential scanning calorimetry
The DSC techniq�e was employed to characterize 
the DTH�loaded SLN. DSC thermograms (Fig�re 4) 
indicate the melting points and corresponding enthalpies 
of DTH, Compritol and SLN. The enthalpy indicates ab�
sol�te heat energy �ptake and is given by the area �nder 
the transition peak. The sharp melting endotherm of DTH 
was observed at 182.1�°C with corresponding enthalpy of 
�35.43 J/g while compritol b�lk showed a melting endo�
therm at 75 °C and enthalpy of �98.64 J/g. The DTH SLN 
showed an endothermic peak at 72.11°C and enthalpy of 
�65.61 J/g. A sho�lder peak was also observed alongside 
at 59.1°C. �n general, melting point depression is observed 
when the b�lk lipid is transformed to nanopartic�late form. 
The decrease in melting point and formation of a sho�lder 
peak is attrib�ted to smaller particle size, lattice defects 
and formation of amorpho�s regions arising o�t of incor�
poration of dr�g molec�les (Chen, et al., 2��6; Sch�bert, 
M�¨ller�Goymann, 2��5). This leads to the corresponding 
decrease in enthalpy from �98.64 to �65.61 J/g.
X-ray diffraction
X�ray diffraction data listed in the following Fig�re 
5 was in good agreement with res�lts established by DSC 
meas�rements. The diffraction pattern of the b�lk matrix 
showed a marked difference from those of the SLN, as 
they showed a relatively sharper peak than the SLN. �t 
was clear that from DTH�loaded SLN, the less ordered 
crystals were the majority and the amorpho�s state 
contrib�ted to the higher dr�g loading capacity as seen 
previo�sly. There was a significant difference between 
the diffraction patterns of dithranol and DTH�loaded 
SLN. �t was confirmed that DTH existed in amorpho�s 
state in the DTH�SLN beca�se of the disappeared sharp 
peak of DTH in the diffraction pattern.
FTIR studies
From FT�R st�dy, the characteristic peak of dr�g 
s�ch as of the aromatic C=O (1597 cm�1), aliphatic C�OH 
(2923 cm�1), aromatic C�H (731, 773 and 1459 cm–1) disa�
ppeared and were replaced by the peak of compritol 888 
ATO where remaining peaks also either shifted or were 
replaced in the �R spectr�m of the form�lation shown in 
Fig�re 6. This established dr�g entrapment in lipid matrix.
Ex-vivo skin penetration studies
The ex-vivo permeation of DTH thro�gh rat skin 
from DTH�loaded SLN ointment was eval�ated �sing a 
Franz diffusion cell. The mean c�m�lative amo�nt diff�sed 
Q (mg/cm2) at each sampling time point was calc�lated. 
The res�lts of diff�sion st�dies are represented graphically 
as Q vs Time in Fig�re 7.
�n the present investigation, DTH�loaded SLN 
ointment of optimized form�lation prod�ced significantly 
higher deposition of DTH in skin (55 %) than marketed 
Ointment of DTH (27 %), as shown in Table V. The stra�
t�m corne�m which represents the principle barrier of 
skin str�ct�re has pore diameters of abo�t 2� nm b�t in 
f�lly hydrated state the pore diameters increase to 4�� nm. 
Th�s, a dr�g�localizing effect in the skin seems possible 
beca�se of hydration of skin by an occl�sion effect of 
FIGURE 3 - Particle size distrib�tion c�rve of optimized batch.
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FIGURE 4 - DSC thermogram of DTH, Compritol ATO 888 and DTH�loaded SLN.
FIGURE 5 - XRD of dithranol, Compritol ATO 888 and DTH�loaded SLN.
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SLN, s�bmicron particle size (219 nm) and high adhesion 
d�e to very high s�rface may explain the increase in skin 
permeation of dithranol SLN. D�e to the lipoidal nat�re 
of SLN, the penetrated dr�g concentrates in the skin and 
remains localized for a longer period of time, th�s enabling 
dr�g targeting for the skin (Pople, Singh, 2��6).
CONCLUSION
The pre�em�lsion followed by �ltrasonication 
techniq�e was �sed to prepare solid lipid nanoparticles 
of reprod�cible sizes in the range of 219 to 348 nm by 
addressing the effects of processing parameters. The ap�
FIGURE 6 - �R spectra of dithranol, Compritol ATO 888 and DTH�loaded SLN.
FIGURE 7 - Mean c�m�lative amo�nt of dr�g diff�sed thro�gh 
rat skin.  DTH SLN ointment ♦DTH Marketed ointment.
TABLE V � Mean amo�nt of dithranol deposited in Rat skin and 
remaining on the skin
Test 
form�lation
Rat skin (%) 
mean (±S�M)
DTH remaining on 
the skin (%) 
Mean (±S�M)
Marketed DTH ointment 27 ± 3.69 44 ± 2.53
DTH�SLN ointment 55 ± 2.23 25 ± 1.87
Mean of three determinations (n=3)
plication of 32 factorial design proved to be a �sef�l tool 
for optimization of DTH�loaded SLN. Using the factorial 
design one can select a s�itable composition of form�la�
tion to obtain DTH�loaded SLN in the size range of 219 to 
348 nm depending on the application of the system. The 
res�lts of the ex-vivo penetration st�dies demonstrated that 
abo�t a two�fold increase in localization of DTH in skin 
was obtained with DTH�loaded SLN entrapped ointment 
compared to plain DTH. 
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